

Disclaimer: This document is an English translation of the original document in Japanese and has been prepared solely for reference purposes. In the event of any discrepancy between this English translation and the original in Japanese, the original shall prevail in all respects.



January 30, 2026

To whom it may concern:

Company name	KISSEI PHARMACEUTICAL CO., LTD.
Representative	Mutsuo Kanzawa, Chairman and CEO (Stock code 4547; Prime Market, Tokyo Stock Exchange)
Contact	Takahide Kitahara, Managing Director, Department Manager of Corporate Finance and Management Department, CFO (Telephone +81-263-25-9081)

Notice Concerning Revisions to Dividend Forecast (Implementation of Commemorative Dividend
for the 80th Anniversary of the Company's Founding)

KISSEI PHARMACEUTICAL CO., LTD. (the "Company") hereby announces that at the Board of Directors meeting held on January 30, 2026, the Company resolved to implement a commemorative dividend as part of the year-end dividend per share for the fiscal year ending March 31, 2026, as well as a commemorative dividend as part of the interim dividend for the fiscal year ending March 31, 2027, as described below.

The Company will celebrate the 80th anniversary of its founding on August 9, 2026. Our medium-term management plan Beyond 80, which was commenced in April 2025, embodies our determination to achieve sustainable growth as an R&D-oriented pharmaceutical company, building on the foundation of the history established by our predecessors. In order to express our gratitude to our shareholders for their continued support and to share with them the determination embodied in Beyond 80, we will implement commemorative dividends in two installments during fiscal year 2026, which marks this 80th anniversary milestone: the year-end dividend for the fiscal year ending March 31, 2026, and the interim dividend for the fiscal year ending March 31, 2027.

The year-end dividend for the fiscal year ending March 31, 2026 is scheduled to be formally determined upon approval at the Board of Directors meeting concerning the financial results to be held in May this year, as well as at the Annual General Meeting of Shareholders scheduled for late June. The interim dividend for the fiscal year ending March 31, 2027 is scheduled to be formally determined upon approval at the Board of Directors meeting to be held in November this year.

1. The year-end dividend for the fiscal year ending March 31, 2026

In addition to the ordinary dividend for the fiscal year ending March 31, 2026, we will pay a commemorative dividend of ¥40 per share.

Dividends per share (Year-end)	Ordinary dividend ¥60
	Commemorative dividend ¥40
	Total ¥100
Total amount of dividends (Forecast)	¥4,145 million

2. The full-year dividend for the fiscal year ending March 31, 2026

Revision Details

	Dividend		
	2nd quarter-end	Year-end	Total
Previous forecast (announced May 7, 2025)	Yen —	Yen 60.00	Yen 120.00
Revised forecast	—	Ordinary dividend 60.00 Commemorative dividend 40.00 Total 100.00	Ordinary dividend 120.00 Commemorative dividend 40.00 Total 160.00
Results for the current fiscal year	60.00	—	—
Results for the previous fiscal year (fiscal year ended March 31, 2025)	45.00	55.00	100.00

3. Commemorative dividend as part of the interim dividend for the fiscal year ending March 31, 2027

We will also pay a commemorative dividend of ¥40 per share as part of the interim dividend for the fiscal year ending March 31, 2027.

The forecast for ordinary dividends (interim and year-end) for the fiscal year ending March 31, 2027 will be announced in the Financial Results for the fiscal year ending March 31, 2026, which will be disclosed in May 2026.

(Reference)

The Company's basic policy on the distribution of profits is as follows:

- The Company will strive to enhance corporate value by prioritizing investments for growth while also paying close attention to ensuring the stable, ongoing provision of dividends to shareholders, thereby maintaining a balance between investment and shareholder returns. Regarding dividends, we aim for a dividend payout ratio of 40% or higher and will implement progressive dividends (ordinary dividends).
- Our basic policy is to make twice-yearly dividend payments, comprising interim and year-end cash dividends. The Board of Directors decides the amount of the interim cash dividend, while the General Meeting of Shareholders decides the amount of the year-end cash dividend. The Company's Articles of Incorporation stipulate that a resolution of the Board of Directors enables the payment of interim cash dividends, with September 30 of each year as the record date.
- The acquisition, disposal, and cancellation of treasury shares will be executed flexibly in accordance with business developments based on resolutions by the Board of Directors, with the primary objective of enhancing shareholder value.
- Regarding internal reserves, we will proactively invest in research and development of pharmaceuticals that patients need, while responding to anticipated changes in administration, regulatory systems, and the advancement of globalization. We believe that this will contribute to future profits and enable appropriate profit distribution to our shareholders.

-End-